2023-02-22

Press Release: BD Onclarity™ HPV Assay Receives FDA Approval for Use with Both BD SurePath™ Liquid-based Pap Test and Hologic ThinPrep® Pap Test

BD Onclarity HPV Assay

The BD Onclarity™ HPV Assay has received FDA Approval for use with both BD SurePath™ Liquid-based Pap Test and Hologic ThinPrep® Pap Test, which expands access to the HPV test that more precisely identifies patients’ risk for cervical cancer.

“When more people with a cervix are better able to manage their health through more accurate and precise testing, we are taking another step forward toward eliminating cervical cancer in our lifetimes,” said Dr. Jeff Andrews, Vice President of Medical Affairs for BD.

ThinPrep is a trademark of Hologic, Inc.

Latest resources

Discover our latest articles, webinars, press releases and updates in women's health.

Specimen Collection for the BD Vaginal Panel
Vaginitis | Webinars & Videos
Specimen Collection for the BD Vaginal Panel
Original research: Performance of a vaginal panel assay compared with the clinical diagnosis of vaginitis
Original research: Performance of a vaginal panel assay compared with the clinical diagnosis of vaginitis
Women in boat
Cervical Cancer | News & Updates
Press Release: New Survey by The Harris Poll Highlights Gaps in Cervical Cancer Screening Access